The Motley Fool
04 Jul 2026, 13:44 UTC · 2h ago
Heartflow vs. Iovance Biotherapeutics: Which Healthcare Stock Is a Better Buy in 2026?
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
The Motley Fool
04 Jul 2026, 13:44 UTC · 2h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
4 claims · each scored for market impact
Iovance Biotherapeutics reported FY 2025 revenue of $263.5 million, representing a 60.6% year-over-year growth rate. — Strong top-line growth in a specialized medical field typically drives bullish sentiment for growth-stage biotech stocks.
+0.60Heartflow reported FY 2025 revenue of approximately $176 million, a 40% increase over the prior year. — Significant revenue growth demonstrates scaling capability for their AI-enabled diagnostic software.
+0.50Iovance Biotherapeutics recorded a net loss of roughly $391 million and negative free cash flow of $336.2 million for FY 2025. — High burn rates and deep losses increase financial risk and the potential need for future dilutive capital raises.
-0.40Continue reading
6 related stories
Top 1 mover · tap to explore
Heartflow reported a net loss of $116.8 million and negative free cash flow of $59.0 million for the year. — Operating losses persist despite revenue growth, though the burn is lower in absolute terms than Iovance's.
-0.30Which stocks this story touches
Significant 60.6% revenue growth and successful commercial scaling of lead therapies, despite high net losses.
Strong top-line revenue growth of 40%, though offset by a net loss and negative free cash flow.
Mentioned as a partner in a critical license agreement supporting Iovance's pipeline.
Mentioned as a partner in a critical license agreement supporting Iovance's pipeline.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
The Motley Fool
2h ago
